Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Androgen suppression therapy (AST) does not significantly decrease bladder cancer (BCa) incidence. However, 5-alpha reductase inhibitors (5-ARIs) show reduced BCa risk, and AST improves patient prognosis, including recurrence-free survival.
Area Of Science
- Oncology
- Urology
- Pharmacology
Background
- The role of androgen suppression therapy (AST) in bladder cancer (BCa) remains debated, with conflicting evidence on its impact on incidence and prognosis.
- Existing research has not established a clear consensus on whether AST affects BCa development or patient outcomes.
Purpose Of The Study
- To conduct an updated systematic review and meta-analysis to clarify the influence of AST on BCa incidence and prognosis.
- To synthesize the latest evidence to resolve controversies surrounding AST's effects on bladder cancer.
Main Methods
- A comprehensive literature search was conducted across major databases (PubMed, Medline, Embase, Web of Science, Cochrane Library).
- Systematic review and meta-analysis of 22 studies involving 700,755 participants.
- Hazard ratios (HR) and odds ratios (OR) were extracted and pooled to assess incidence and prognosis.
Main Results
- AST showed no significant association with a decreased incidence of BCa (OR: 0.92, P=0.342).
- Subgroup analysis revealed that 5-alpha reductase inhibitors (5-ARIs) significantly reduced BCa risk (OR: 0.83, P<0.001), unlike androgen deprivation therapy (ADT).
- AST significantly improved recurrence-free survival (HR: 0.69, P=0.023) and overall survival (OS) in BCa patients, particularly those receiving 5-ARIs (HR: 0.82, P=0.037).
Conclusions
- While AST does not appear to lower overall BCa incidence, 5-ARIs demonstrate a protective effect.
- AST is associated with improved prognosis in bladder cancer patients, including enhanced recurrence-free and overall survival.
- The findings suggest a nuanced role for AST, with specific agents like 5-ARIs showing promise in BCa prevention and treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...